- Home
- GNTA vs IMMX Comparison
GNTA vs IMMX Comparison
Compare GNTA & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- IMMX
- Stock Information
- Founded
- GNTA 2014
- IMMX 2014
- Country
- GNTA Italy
- IMMX United States
- Employees
- GNTA N/A
- IMMX N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- GNTA Health Care
- IMMX Health Care
- Exchange
- GNTA Nasdaq
- IMMX Nasdaq
- Market Cap
- GNTA 64.3M
- IMMX 65.5M
- IPO Year
- GNTA 2021
- IMMX 2021
- Fundamental
- Price
- GNTA $3.44
- IMMX $2.18
- Analyst Decision
- GNTA Strong Buy
- IMMX Strong Buy
- Analyst Count
- GNTA 1
- IMMX 1
- Target Price
- GNTA $25.00
- IMMX $7.00
- AVG Volume (30 Days)
- GNTA 9.1K
- IMMX 198.5K
- Earning Date
- GNTA 01-01-0001
- IMMX 08-08-2025
- Dividend Yield
- GNTA N/A
- IMMX N/A
- EPS Growth
- GNTA N/A
- IMMX N/A
- EPS
- GNTA N/A
- IMMX N/A
- Revenue
- GNTA N/A
- IMMX N/A
- Revenue This Year
- GNTA N/A
- IMMX N/A
- Revenue Next Year
- GNTA N/A
- IMMX N/A
- P/E Ratio
- GNTA N/A
- IMMX N/A
- Revenue Growth
- GNTA N/A
- IMMX N/A
- 52 Week Low
- GNTA $2.74
- IMMX $1.26
- 52 Week High
- GNTA $7.28
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- GNTA 43.44
- IMMX 44.18
- Support Level
- GNTA $3.41
- IMMX $2.16
- Resistance Level
- GNTA $3.68
- IMMX $2.29
- Average True Range (ATR)
- GNTA 0.29
- IMMX 0.16
- MACD
- GNTA -0.01
- IMMX 0.01
- Stochastic Oscillator
- GNTA 16.54
- IMMX 48.84
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.